| Primary |
| Product Used For Unknown Indication |
30.7% |
| Renal Transplant |
20.6% |
| Liver Transplant |
10.7% |
| Prophylaxis Against Graft Versus Host Disease |
6.2% |
| Rheumatoid Arthritis |
4.6% |
| Prophylaxis Against Transplant Rejection |
4.4% |
| Heart Transplant |
3.5% |
| Lung Transplant |
3.2% |
| Bone Marrow Transplant |
3.0% |
| Immunosuppressant Drug Therapy |
2.3% |
| Stem Cell Transplant |
1.9% |
| Hypertension |
1.4% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Transplant |
1.0% |
| Immunosuppression |
1.0% |
| Cord Blood Transplant Therapy |
0.9% |
| Colitis Ulcerative |
0.8% |
| Pancreas Transplant |
0.8% |
| Diabetes Mellitus |
0.8% |
| Prophylaxis |
0.7% |
|
| Death |
24.6% |
| Off Label Use |
10.3% |
| Drug Ineffective |
7.7% |
| Pregnancy |
5.3% |
| Sepsis |
5.1% |
| Hospitalisation |
5.1% |
| Thrombotic Microangiopathy |
5.0% |
| Vomiting |
4.0% |
| Transplant Rejection |
3.9% |
| Acute Graft Versus Host Disease |
3.4% |
| Renal Failure |
3.1% |
| Pneumonia |
3.0% |
| Treatment Noncompliance |
3.0% |
| Tremor |
3.0% |
| Renal Transplant |
2.6% |
| Respiratory Failure |
2.6% |
| Renal Impairment |
2.4% |
| Urinary Tract Infection |
2.0% |
| Kidney Transplant Rejection |
2.0% |
| Graft Versus Host Disease |
1.9% |
|
| Secondary |
| Product Used For Unknown Indication |
22.9% |
| Renal Transplant |
16.9% |
| Rheumatoid Arthritis |
9.2% |
| Drug Use For Unknown Indication |
7.5% |
| Heart Transplant |
4.9% |
| Hypertension |
4.4% |
| Prophylaxis |
4.2% |
| Prophylaxis Against Transplant Rejection |
4.0% |
| Infection Prophylaxis |
3.7% |
| Immunosuppression |
3.0% |
| Liver Transplant |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Graft Versus Host Disease |
2.8% |
| Stem Cell Transplant |
2.6% |
| Immunosuppressant Drug Therapy |
1.9% |
| Lung Transplant |
1.8% |
| Colitis Ulcerative |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.0% |
| Osteoporosis |
1.0% |
| Adult T-cell Lymphoma/leukaemia |
1.0% |
|
| Off Label Use |
12.8% |
| Vomiting |
7.1% |
| Transplant Rejection |
7.1% |
| Stomatitis |
6.8% |
| Renal Impairment |
6.7% |
| Sepsis |
5.6% |
| White Blood Cell Count Decreased |
5.6% |
| Renal Failure Acute |
5.4% |
| Drug Ineffective |
5.2% |
| Hypertension |
4.4% |
| Nausea |
4.1% |
| Tremor |
3.8% |
| Pyrexia |
3.5% |
| Renal Failure |
3.4% |
| Thrombotic Microangiopathy |
3.3% |
| Lung Neoplasm Malignant |
3.3% |
| Immunosuppressant Drug Level Increased |
3.1% |
| Pneumonia |
3.1% |
| Ileus |
2.9% |
| Pulmonary Tuberculosis |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.9% |
| Drug Use For Unknown Indication |
11.3% |
| Renal Transplant |
9.6% |
| Rheumatoid Arthritis |
9.4% |
| Prophylaxis Against Transplant Rejection |
6.4% |
| Prophylaxis |
5.5% |
| Hypertension |
4.0% |
| Nuclear Magnetic Resonance Imaging |
3.4% |
| Immunosuppression |
3.4% |
| Pain |
2.6% |
| Liver Transplant |
2.2% |
| Infection Prophylaxis |
2.0% |
| Diabetes Mellitus |
1.8% |
| Osteoporosis |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Angiogram |
1.5% |
| Heart Transplant |
1.4% |
| Colitis Ulcerative |
1.2% |
| Nausea |
1.1% |
| Hepatitis C |
1.1% |
|
| Vomiting |
12.6% |
| White Blood Cell Count Decreased |
8.3% |
| Sepsis |
7.6% |
| Pyrexia |
6.0% |
| Transplant Rejection |
5.7% |
| Renal Failure Acute |
5.4% |
| Weight Decreased |
5.2% |
| Renal Failure |
5.0% |
| Death |
4.8% |
| Pneumonia |
4.4% |
| Urinary Tract Infection |
4.3% |
| Therapeutic Response Decreased |
4.2% |
| Nephrogenic Systemic Fibrosis |
4.1% |
| Kidney Transplant Rejection |
4.0% |
| Thrombocytopenia |
3.9% |
| Interstitial Lung Disease |
3.1% |
| Renal Impairment |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Liver Transplant Rejection |
2.7% |
| Renal Transplant |
2.7% |
|
| Interacting |
| Renal Failure Chronic |
16.0% |
| Product Used For Unknown Indication |
9.5% |
| Renal Transplant |
8.4% |
| Heart Transplant |
8.0% |
| Fungal Infection |
7.3% |
| Epilepsy |
5.3% |
| Systemic Lupus Erythematosus |
5.3% |
| Immunosuppression |
5.2% |
| Hypertension |
5.1% |
| Prophylaxis |
3.9% |
| Hiv Infection |
3.6% |
| Diabetes Mellitus |
3.5% |
| Colitis Ulcerative |
2.9% |
| Oral Candidiasis |
2.9% |
| Prophylaxis Against Transplant Rejection |
2.4% |
| Anaemia |
2.1% |
| Blood Pressure Increased |
2.1% |
| Dyslipidaemia |
2.1% |
| Immunosuppressant Drug Therapy |
2.1% |
| Stress |
2.1% |
|
| Drug Interaction |
25.0% |
| Renal Impairment |
10.0% |
| Weight Decreased |
10.0% |
| Immunosuppressant Drug Level Increased |
8.3% |
| Renal Failure Acute |
6.1% |
| Tremor |
5.0% |
| Staphylococcal Infection |
4.4% |
| Systemic Mycosis |
4.4% |
| Drug Level Below Therapeutic |
3.3% |
| Drug Level Decreased |
3.3% |
| Drug Level Increased |
2.8% |
| Overdose |
2.8% |
| Renal Function Test Abnormal |
2.2% |
| Vomiting |
2.2% |
| Acute Graft Versus Host Disease |
1.7% |
| Clonic Convulsion |
1.7% |
| Renal Failure |
1.7% |
| Toxicity To Various Agents |
1.7% |
| Underdose |
1.7% |
| Urinary Tract Infection |
1.7% |
|
